Built by Claude FableConcerns & Risks -- 5/10
| Risk | Severity | Sizing |
|---|---|---|
| Earnings quality / investment marks | High | $7.77B portfolio; a 10% reversal is ~-$0.70/share. Core Q1 EPS was ~$3.14 vs $3.13 consensus |
| Zero-cushion print in 5 days | High | Guided $3.25-3.27 vs $3.27 consensus, stock +21% off the 50-day MA |
| 2H organic reacceleration promise | High | Q2 organic guided ~6%, decelerating from ~8.7%; FY needs ~9-10% in 2H |
| Permanent leverage step-up | Medium | ~$1.4B/yr fixed charge ahead of shareholders; tangible equity roughly -$31.8B |
| AI / seat erosion | Medium, structural | Slow-burn; ~95% recurring and $67.9B RPO mean it takes years to appear in revenue |
| Microsoft E5 bundling | Medium | Dynamics + Copilot at near-zero incremental price to existing E5 estates |
| Goodwill impairment | Low | ~5x fair-value headroom vs $172B cap; ~3.5x at the 52-week low; non-cash anyway |
| ASR final settlement (Q3 FY27) | Low | Residual ~20% of expected shares; ~$0.17 EPS sensitivity |
| Key-man / governance | Medium | Chair+CEO in one person, CFO+COO in another, no named successor |
Gross debt went from $14.44B ($10.44B noncurrent plus $4.0B current) to $39.28B, all noncurrent, to fund the $25B ASR. Q1 interest expense was $317M on only a partial period, implying a run-rate meaningfully above $1.4B once the full year loads. Stockholders' equity fell from $59,142M to $34,235M; against $59.3B of goodwill, tangible book equity is roughly negative $31.8B.
That sounds alarming and is worth stating plainly, but it does not threaten the enterprise:
- Interest cover is roughly 10x on FY27E non-GAAP operating income of ~$15.8B.
- Net debt is $27.4B, roughly 1.8x FY27E FCF of ~$15.1B.
- $11.8B of cash and marketable securities on hand.
- FCF of ~$15B comfortably services a ~$1.4B charge.
The correct characterisation is that the ASR is a haircut to FCF growth, not a threat to the FCF stream -- and that is exactly what the guidance says, with OCF and FCF growth cut to 4–5%. The genuine criticism is one of optionality, not solvency: the cushion was spent as a valuation trade at the moment AI capital intensity and M&A flexibility carry their highest option value.
This is the risk most likely to bite inside the next week. Salesforce marks its $7.77B strategic investment portfolio through the income statement and does not exclude the result from non-GAAP EPS. In FY27Q1 that contributed +$558M, or $0.51 per share.
Normalise FY27Q1 for both the investment gain and the ASR share-count benefit -- the latter fair to strip only here, because consensus was set before the ASR existed -- and core EPS was approximately $3.14 against a $3.13 consensus. The quarter that printed a 24% beat was, on an apples-to-apples operating basis, an in-line quarter. A 10% reversal on the portfolio is roughly -$0.70 per share and breaks the six-quarter streak on its own, with no operating deterioration whatsoever.
Management has committed to organic revenue reacceleration in the second half of FY27. The arithmetic is demanding: Q2 organic is guided to roughly 6%, decelerating from Q1's ~8.7%, which means the full-year guide requires roughly 9–10% organic in the second half.
The leading indicator is not confirming yet. cRPO growth is flat at ~13% cc and is itself Informatica-assisted. Management points instead to net new AOV outpacing AOV growth for four consecutive quarters -- a mechanistically coherent bridge, but unquantified, so it cannot be audited from outside. Meanwhile they concede ongoing weakness in Marketing and Commerce plus increased softness in Tableau.
The honest framing: management has offered a coherent but unverifiable leading indicator with four quarters of direction, and simultaneously raised the full-year revenue guide. That is not "no evidence." It is evidence an outsider cannot check.
Goodwill impairment. The 56%-of-assets headline invites alarm, but impairment testing is against fair value, not book. A $172.2B market cap against $34.2B of book equity leaves roughly 5x headroom, and about 3.5x even at the 52-week low of $146.32. Any write-down would also be non-cash and would not touch the FCF that supports the valuation case.
ASR settlement. The residual is roughly 20% of expected total shares, settling in Q3 FY27, with EPS sensitivity around $0.17. Real but small.
Demand shock. With ~95% recurring revenue, 77% gross margins, $33.6B of cRPO covering 73% of the FY27 revenue guide and $67.9B of total RPO, a demand deterioration takes years rather than quarters to reach reported revenue. This is genuine structural protection and is the main reason this dimension is not a 3 or 4.
| Dimension | First pass | Final | Reason for change |
|---|---|---|---|
| Financial Trends | 6 | 7 | First pass imported FY27 forward guidance into a realised-trajectory dimension, then scored it again here. Also missed that the FY27 guide was raised, not cut. |
| Thematic Exposure | 5 | 6 | The load-bearing +7% cc figure blends Sales/Service with the legacy Marketing/Commerce drag. Three deal-level seat datapoints were omitted. |
| Management Quality | 6 | 6 | Held, but two supporting criticisms withdrawn as unsupported by the transcripts. |
| Investor Sentiment | 7 | 7 | Unchanged. |
| Concerns & Risks | 5 | 5 | Held. 6 was arguable, but the $7.77B portfolio into a zero-cushion print is an uncontrolled near-dated hazard. |
| Composite | 5.55 | 6.15 | Also corrected: the same four objections were being charged across four to five dimensions each. |
The structural correction worth recording: the first pass charged the ASR's interest cost in three separate dimensions while also stripping its offsetting $0.23 EPS benefit. You may charge the cost or strip the benefit, not both. Similarly, one factual error was corrected -- revenue attrition was disclosed on four of the last six calls, not six, since FY26Q2 does not mention it at all.